EurekaMag.com logo
+ Site Statistics
References:
53,517,315
Abstracts:
29,339,501
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Stimulating capacity of leukemia cells from acute nonlymphocytic leukemia chronic myelogenous leukemia blastic crisis of chronic myelogenous leukemia and chronic myelo monocytic leukemia in allogeneic 1 way mixed lymphocyte tumor cell reaction



Stimulating capacity of leukemia cells from acute nonlymphocytic leukemia chronic myelogenous leukemia blastic crisis of chronic myelogenous leukemia and chronic myelo monocytic leukemia in allogeneic 1 way mixed lymphocyte tumor cell reaction



Acta Haematologica Japonica 43(5): 796-804



The stimulating capacity of myelogenous leukemia cells on the allogeneic mixed lymphocyte tumor cell reaction (MLTR) was investigated. Leukemia cells from 13 of 14 cases with acute myelogenous leukemia (AML) and from 9 of 12 cases with acute monocytic (AMoL) or myelomonocytic leukemia (AMMoL) had moderate to strong stimulating capacity, as compared to that of normal peripheral lymphocyte on mixed lymphocyte reaction. Blastic leukemia cells from all of 10 patients with chronic myelogenous leukemia blast crisis possessed potent stimulating capacity, while normal peripheral neutrophils, myelocytes and metamyelocyte fraction and neutrophils fraction from chronic myelogenous leukemia had negligible or little stimulating capacity. The stimulating capacity was not observed in leukemia cells from 1 case with peroxidase negative, Ia-like antigen positive and TdT [terminal deoxynucleotidyl transferase] activity positive AML and from 3 cases with AMoL, which corresponds to pure monocytic leukemia. The stimulating capacity was observed not only on leukemia cells with Ia-like antigen but also frequently on leukemia cells without Ia-like antigen. Lymphocyte-defined antigens other than Ia-like antigen, including tumor specific antigens and other histocompatibility alloantigen, should be considered to explain the stimulating capacity of leukemia cells from AML, AMoL and AMMoL on allogeneic MLTR.

(PDF 0-2 workdays service: $29.90)

Accession: 006480460

Download citation: RISBibTeXText



Related references

Stimulating capacity of leukemia cells from acute non-lymphocytic leukemia, chronic myelogenous leukemia, blastic crisis of chronic myelogenous leukemia, and chronic myelomonocytic leukemia in allogenic 'one way' mixed lymphocyte tumor cell reaction. Nihon Ketsueki Gakkai Zasshi 43(5): 796-804, 1980

Immunological characterization of normal and leukemia associated antigens of acute myelo monocytic leukemia and chronic myelogenous leukemia in blast crisis. Cancer Research 38(3): 716-722, 1978

Detection of both thymus derived cell and ia like antigens on cells from patients with acute myelo monocytic leukemia and chronic myelogenous leukemia in blast crisis. Cancer Research 39(12): 4810-4815, 1979

Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant. Journal of Immunology 187(4): 1653-1663, 2011

Philadelphia-chromosome-positive T-lymphoblastic leukemia: acute leukemia or chronic myelogenous leukemia blastic crisis. Acta Haematologica 113(3): 181-189, 2005

Butadiene cancer exposure-response modeling: based on workers in the styrene-butadiene-rubber industry: total leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, and chronic myelogenous leukemia. Regulatory Toxicology and Pharmacology 60(3): 332-341, 2011

A comprehensive review of occupational and general population cancer risk: 1,3-Butadiene exposure-response modeling for all leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, myeloid neoplasm and lymphoid neoplasm. Chemico-Biological Interactions 241: 50-58, 2016

Monitoring trace elements in cells from the blood of patients with acute myelo blastic leukemia chronic lymphocytic leukemia and chronic granulocytic leukemia. Haematologica 67(3): 437-441, 1982

Blastic crisis mimicking acute leukemia as 1st manifestation of chronic myelogenous leukemia 3 cases. Sangre (Saragossa) 26(1): 96-103, 1981

Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Research 53(15): 3603-3610, 1993

Vindesine and prednisone in the treatment of relapsed lympho malignancies blastic crisis of chronic myelocytic leukemia and acute myelo monocytic leukemia. Brade, W , G A Nagel And S Seeber (Ed ) Beitraege Zur Onkologie, Contributions to Oncology, Vol 6 Proceedings Of The International Vinca Alkaloid Symposium: Vindesine; Joint Event Of Arbeitsgemeinschaft Internistische Onkologie Der Deutschen Krebsgesellschaft (Internal Oncology Working Group Of The German Cancer Society) And Eli Lilly Gmbh, Germany, Frankfurt Am Main, West Germany, Nov 1980 Xii+458p S Karger: Basel, Switzerland; New York, N Y , Usa Illus Paper P143-150, 1981

Association of the translocation (15;17) with malignant proliferation of promyelocytes in acute leukemia and chronic myelogenous leukemia at blastic crisis. Blood 67(2): 270-274, 1986

Donor cell derived acute myelogenous leukemia developing post allogeneic bone marrow transplant for a patient with chronic myelogenous leukemia. Journal of Cellular Biochemistry Supplement 0(18B): 63, 1994

Lymphoid blast crisis of chronic myelogenous leukemia occurring more than 11 years after receiving an allogeneic bone marrow transplant for chronic myelogenous leukemia in myeloid blast crisis at onset. Bone Marrow Transplantation 31(3): 211-213, February 1, 2003

A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia. Leukemia 10(5): 766-768, 1996